2 results
Approved WMOCompleted
Primary objectiveTo evaluate preliminary efficacy of itacitinib (INCB039110) on spleen volume reduction (SVR) from baseline at Week 24 in the 2 following cohorts of MF subjects:- Cohort A: in combination in subjects with ruxolitinib low dose (less…
Approved WMORecruiting
To investigate the feasibility and safety of the DMUA-HIFU system for treatment of atherosclerotic plaques.